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Breastfeeding is recommended for infants born to HIV-infected women in low-income set-
tings. Both breastfeeding and HIV-infection are energy demanding. Our objective was to
explore how exclusive and predominant breastfeeding changes body mass index (BMI)
among breastfeeding HIV1-positive women participating in the ANRS12174 trial (clinical
trial no NCT0064026).
Methods
HIV-positive women (n = 1 267) with CD4 count >350, intending to breastfeed HIV-negative
infants were enrolled from Burkina Faso, South Africa, Uganda and Zambia and counselled
on breastfeeding. N = 1 216 were included in the analysis. The trial compared Lamivudine
and Lopinavir/Ritonavir as a peri-exposure prophylaxis. We ran a linear mixed-effect model
with BMI as the dependent variable and exclusive or predominant breastfeeding duration as
the key explanatory variable.
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Results
Any breastfeeding or exclusive/predominant) breastfeeding was initiated by 99.6% and
98.6% of the mothers respectively in the first week after birth. The median (interquartile
range: IQR) duration of the group that did any breastfeeding or the group that did exclusive
/predominant breastfeeding were 9.5 (7.5; 10.6) and 5.8 (5.6; 5.9)) months, respectively.
The median (IQR) age, BMI, CD4 count, and HIV viral load at baseline (day 7) were 27
(23.3; 31) years, 23.7 (21.3; 27.0) kg/m2, 530 (432.5; 668.5) cells/μl and 0.1 (0.8; 13.7)1000
copies/mL, respectively. No major change in mean BMI was seen in this cohort over a 50-
week period during lactation. The mean change between 26 and 50 weeks after birth was
0.7 kg/m2. Baseline mean BMI (measured on day 7 postpartum) and CD4 count were posi-
tively associated with maternal BMI change, with a mean increase of 1.0 kg/m2 (0.9; 1.0) per
each additional baseline-BMI kilogram and 0.3 kg/m2 (0.2; 0.5) for each additional CD4 cell/
μl, respectively.
Conclusion
Breastfeeding was not negatively correlated with the BMI of HIV-1 infected Sub-Saharan
African mothers. However, a higher baseline BMI and a CD4 count >500 cells/μl were asso-
ciated with maternal BMI during the exclusive/ predominant breastfeeding period. Consider-
ing the benefits of breast milk for the infants and the recurrent results from different studies
that breastfeeding is not harmful to the HIV-1-infected mothers, this study also supports the
WHO 2016 guidelines on infant feeding that mothers living with HIV should breastfeed
where formula is not safe for at least 12 months and up to 24 months, given that the right
treatment or prophylaxis for the infection is administered. These findings and conclusions
cannot be extrapolated to women who are immune-compromised or have AIDS.
Introduction
HIV infection is among the leading causes of mortality among women of childbearing age [1].
It will be associated with an increased risk of infections from non-obstetric and direct obstetric
causes, making HIV-infected mothers more vulnerable than uninfected mothers [2,3]. HIV in
pregnancy contributed to high maternal mortality rates with a 9% contribution in Sub-Saharan
Africa (SSA) between 1990 and 2008. It is the leading cause of death during pregnancy and the
postpartum period in countries with a high prevalence of HIV [4,5]. A recent meta-analysis
pointed out clearly the significance of HIV infection in global maternal mortality rates, with
an estimated 5% pregnancy-related deaths worldwide and 25% in SSA [6]. The reasons of this
high mortality in HIV-infected women are unclear. The risk of obstetric complications may be
increased in HIV-infected women or pregnancy might accelerate HIV progression [6–8].
Weight loss and low body mass index (BMI) can serve as markers of HIV disease progres-
sion. Weight has been used to diagnose clinical AIDS disease; a 10% weight loss in the absence
of any other evident cause was one of the early WHO clinical criteria in areas without laborato-
ries [9–13]. Individuals with asymptomatic HIV need an extra 10% energy intake to maintain
body weight, which increases to 20–30% among those who have symptomatic HIV [14,15].
Moreover during pregnancy and lactation, the woman’s body in a normal physiological state
undergoes massive energy trade-off seen through weight changes, typically an increase during
pregnancy and a loss to pre-pregnancy weight during lactation [16,17].
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There has been a dilemma during the last 20 years in choosing between exclusive breast-
feeding (EBF) and replacement feeding [18], which was only considered on the basis of the
best nutritional and survival outcome for the infant. Specifically, in the pre-ART period the
focus was on ensuring the HIV-free survival of infants exposed to HIV.However, in socio-eco-
nomically deprived settings, breastfeeding has proven to be a key survival strategy for infants
born to women living with HIV because increased morbidity and mortality have been associ-
ated with replacement feeding [19]. After 2010, availability of, and accessibility to, antiretrovi-
ral drugs during pregnancy and lactation have increased. The programs of prevention of
mother-to-child transmission (PMTCT) of HIV yielded 2 antiretroviral (ARV) prophylaxis
options, including regimen A (prophylactic ARV drugs are given to the mothers and children
during the risk period); and regimen B (antiretroviral therapy is given to the mothers during
the risk period), or regimen B+ (extending regimen B to lifelong treatment) [20]. In the
WHO’s 2010 recommendations, women living with HIV who opted to breastfeed were recom-
mended to practice exclusive breastfeeding (EBF) until the infant was 6 months old, introduce
appropriate complementary foods thereafter, and continue breastfeeding for the first 12
months of the infant’s life. The 2016 recommendations recommend mothers living with HIV
to prolong the breastfeeding period to up to 24 months, as advised for the general population
(i.e. HIV-uninfected women). The importance of having a nutritionally adequate and safe diet
for the child, a lifelong ARV therapy, with adherence counselling and support for breastfeed-
ing for the mothers, is stressed as a prerequisite before breastfeeding can be gradually stopped.
Thus, option B+ has made it easier for countries to opt for exclusive breastfeeding for 6
months as the preferred early child feeding option [21–23].
Regarding the mother’s health, studies have reached inconsistent conclusions as to the
effect of breastfeeding on the weight of those infected with HIV [14,24,25]. The South African
Vertical Transmission Study that compared women practicing EBF compared to those opting
for replacement feeding or mixed feeding concluded that a) HIV-infected and uninfected
mothers experienced similar weight loss over 24 months; and b) postpartum weight change
was not associated with feeding practices for the first 5 months of the baby’s life. [14]. In this
study, the mothers received a single-dose of nevirapine as PMTCT treatment. The Kesho Bora
study, a combination of a randomized clinical trial and a prospective cohort study, comprised
3 parts: part IA included women with CD4 count <200 cells/mm3, receiving Zidovudine
(AZT), lamivudine and nevirapine (NVP) twice daily; part IB included women with CD4
count>500 cells/mm3, receiving AZT 300 mg taken by the mother twice daily starting from
34 to 36 weeks of pregnancy until the onset of labor, plus one 600 mg dose of AZT and one
200 mg dose of NVP at the onset of labor; and part II or the RCT part, included women with a
CD4 count between 200 and 500 cells/mm3, randomized to receive the same prophylaxis as
part IB or triple-ARV prophylaxis (AZT [300 mg], 3TC [150 mg] and lopinavir/ritonavir
[LPV/r, 400 mg/100 mg]) twice daily from 34 to 36 weeks of pregnancy, through delivery and
during breastfeeding to a maximum of 6 months postpartum [26]. It showed that 6 months of
breastfeeding was not detrimental to the weight of well-nourished HIV-infected mothers [24].
A study in Zambia randomized women into a short-duration (4 months EBF and abrupt
weaning) and a long-duration (mean duration of 16 months including 6 months EBF) breast-
feeding period; it showed a net weight gain in HIV-infected women breastfeeding from 4 up to
24 months postpartum [27]. All mothers in the Zambian study were categorized into low
(350 cells/μl) and high (>350 cells/ μl) CD4 count groups. The subjects had received a sin-
gle-dose nevirapine as MTCT prophylaxis. When antiretroviral treatment became available in
May 2004, 26 women were started on the first-line regimen. CD4 count was associated with
lower weight. Effects of lactation in women with low CD4 counts were similar to the effects in
women with higher CD4 counts. In contrast, two Kenyan studies [28,29] found weight loss
Changes in BMI and heamoglobin in HIV-1 breastfeeding mothers
PLOS ONE | https://doi.org/10.1371/journal.pone.0177259 May 9, 2017 3 / 16
among HIV-infected breastfeeding mothers compared to mothers using formula feeding.
Though the design of these studies made a comparison difficult with the precedent studies.
they were worse in showing adverse outcomes due to breastfeeding, which included more
maternal deaths. These studies in Nairobi, representing two different analyses of the same
data, compared mothers who breastfed from delivery until 2 years of age to formula-feeding in
a cohort study where all the pregnant women received a short course of zidovudine prophy-
laxis. When antiretroviral treatment became available, women were referred to highly active
antiretroviral treatment programs.
HIV infection also seems to be detrimental to maternal hemogloblin concentration [30,31],
which could be worsened by the use of some antiretroviral substances [32–34]. Our aim was
therefore to explore within the ANRS12174 trial population how breastfeeding might change
BMI and hemoglobin concentration. We also assessed other factors that might have influenced
weight changes of HIV-infected mothers during lactation.
Methods
Study design
The ANRS 12174 clinical trial in Ouagadougou (Burkina Faso), East London (South Africa),
Mbale (Uganda) and Lusaka (Zambia) was conducted from 2009 to 2013, the protocol and the
primary analysis having been published [35,36]. Briefly, pregnant women who tested positive
for HIV-1 infection in the context of routine antenatal clinic service making them ineligible
for highly active antiretroviral therapy because their CD4+ count was>350 cells/ml, who had
to be at least 18 years old and who were planning to breastfeed, were identified at antenatal
clinics between 28 and 40 weeks of pregnancy. They received a pre-test counselling session
before testing for HIV infection. As part of the post-test session, they were informed of the dif-
ferent feeding options for their babies. Only women intending to breastfeed were referred to
the research clinic for further assessment of the inclusion criteria during the antenatal period,
and again with their child within 6 days after birth, for enrolment and randomisation at day 7
postpartum. From 28 weeks of pregnancy to day 7 after birth, programmatic mother-to-child
transmission prophylaxis was followed with antepartum zidovudine, intrapartum single dose
nevirapine, and zidovudine-lamivudine for mothers and nevirapine for infants for 7 days post-
partum. The intervention implemented during the trial was infant prophylaxis in the breast-
feeding period starting from 7 days to 50 weeks of age with either lopinavir/ritonavir or
lamivudine. Twins and triplets, infants with a positive HIV-1 DNA PCR test result at day 7
(+/- 2) postpartum, and low birth-weight or ill babies (ranked grade II or above of the ANRS
classification for adverse events) on the day of enrolment were excluded [37].
Lamivudine, generally well tolerated and accepted, has been widely used in research and
clinical trials. The lopinavir/ritonavir paediatric formulation has been a very promising pro-
phylactic combination with low risks for resistance, high antiviral potency and a good safety
profile [35]. However, it is known to be distasteful (https://www.medicines.org.uk/emc/
medicine/4602; https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf),
which was thought to matter less when introduced very early.
Data management and analysis
Data were collected on a paper case-report form or directly entered online using the Electronic
Data capture system OpenClinica™ (www.openclinica.com). Twenty-four hours and one week
breastfeeding recalls were collected during the enrolment visit on day 7 (±2) after birth and
during the 13 monthly-scheduled follow-up visits that started at week 2. During these visits,
mothers were particularly asked if they gave their infants other foods/liquids in addition to
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breastmilk. Pre-lacteal feeding data which was defined as any food item except mothers’ milk
given to infants before initial breastfeeding) were also collected at the enrolment visit. The data
were collected by trained physicians, pharmacists, biologists and counsellors. Seca-brand scales
and stadiometers were used to measure the mother’s height and weight. Weights were rounded
to the nearest 10 grams and the height at the nearest millimetre. Weight and height were mea-
sured twice based on the WHO guidelines (http://www.who.int/childgrowth/training/en/).
We categorized mothers at each visit into the following groups: 1) exclusive breastfeeding,
EBF (only breastmilk being given to the infant without any other kind of food or liquid, except
medically prescribed drugs or vitamins); 2) predominant breastfeeding, PBF (breastmilk with
some liquid-based food, such as juice, tea, sugar-water and salt-water including glucose with-
out any kind of formula or animal milk); and 3) mixed feeding, MF (breastmilk with other
solid or liquid-based food, including other kinds of milk). We thereafter combined EBF and
PBF into one group called “exclusive and predominant breastfeeding” (EPBF) because the
number of women who practised PBF was too small and the practice was occasional. The
entire cohort was in this latter group at the beginning of the study, which was followed up to
detect any change in EPBF status, i.e. change to mixed feeding by week 26 post-partum, which
is the time when exclusive breastfeeding is supposed to be changed to complementary feeding.
Data on maternal dietary intake were not collected
In a bivariate analysis, we compared the mean BMI at weeks 14, 26, 38 and 50 with the
mean BMI at day 7 (baseline) post-delivery using Bonferroni-corrected paired t-tests for multi-
ple comparisons. Data were presented for all 4 sites, by country and baseline BMI groups.
Group 1 included women with BMI<18.5 kg/m2 (underweight), Group 2 included those with
a BMI between 18.5 and 24.9 kg/m2 (normal range), and Group 3 were those with a BMI25
kg/m2 (overweight) according to the WHO classification system (http://apps.who.int/bmi/
index.jsp?introPage=intro_3.html) [38]. We also compared the mean hemoglobin concentra-
tion at week 38 with week 14 (because this data was available only for these visits) in the same
way. To take into account the inter-country and inter-subject variability, we ran a further lin-
ear mixed-effect model with BMI as the dependent variable and EPBF duration as the key
explanatory variable adjusted for baseline BMI and other covariates, including the mother’s
viral load, CD4 count, hemoglobin concentration, HIV stage, mode of delivery (vaginal versus
C-section), parity, age, education level, marital status and occupation. The child’s characteris-
tics included its gender, birth weight, treatment group and the breastfeeding initiation time.
We checked that the total variance due to country effect was always >10% by running a vari-
ance component analysis and a likelihood ratio test to confirm that the differences related to
countries were significant. Variables with p0.20 in the bivariate analysis were considered for
the multivariate analysis in the pooled-data analysis for all the countries. We also stratified by
country and ran the same multivariate analysis, introducing a country-specific socio-economic
status (SES) index.
The principal component methods was used to construct the SES index, [39]. Sixteen asset
variables were variously included in the principal component analysis, considering country
specificities. The first components (explaining 33, 39, 29 and 34% of the variation for Burkina
Faso, South Africa, Uganda and Zambia, respectively) were retained to weigh the variables and
calculate the index at the household level. This was the sum of the different variables’ weight/
score per subject, which was divided into tertiles.
For continuous variables, the mean values with 95% confidence interval (CI) were esti-
mated, and for categorical variables, percentages were used. Medians (IQR) were also reported.
Associations between variables were tested using the Chi-square test for categorical variables.
STATA/SE 13.1 (4905 Lakeway Drive College Station, Texas 77845 USA) was the statistical
software used.
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Ethics
Prior to enrolment, the mothers signed written informed consent and assent forms for them-
selves and their children, respectively. The trial was conducted according to the sponsor
(ANRS) ethic charter, Good Clinical Practices and the principles of the Helsinki declaration.
The protocol had obtained approval from the relevant ethical committees, including the Ethi-
cal Committee for Health Research in Burkina Faso, the Biomedical Research Ethics Commit-
tee in Zambia, the Uganda National Council for Science and Technology, the Stellenbosch
University ethical committees, the Medicines Control Council in South Africa and the
Regional Committee for Medical Research Ethics of Norway.
Results
In the ANRS 12174 trial, 1,273 mother-infant pairs were randomized and 6 were excluded due
to protocol violations. Of the remaining 1,267 participants, 204 were from Ouagadougou, 222
from East London, 278 from Mbale and 563 from Lusaka. In all, 42 were excluded from analy-
sis due to lack of breastfeeding data after inclusion, 7 due to inaccurate feeding duration data
and 2 women had no data on weights. Thus 1,216 subjects were included in the analysis.
At baseline (Table 1), South Africa had the largest mean BMI, and the highest frequency of
single women and C-section delivery. Burkina Faso participants had the lowest HIV viral load,
the lowest hemoglobin concentration, and the lowest literacy and formal occupation fre-
quency. Breastfeeding was initiated later in Burkina Faso where EPBF frequency was also the
lowest the first week.
During pregnancy antiretroviral prophylaxis was given 100% of women in all 4 countries
Breastfeeding duration and BMI changes
The median (Interquartile Range (IQR)) durations of EPBF and any breastfeeding were 5.8
(5.6; 5.9) and 9.5 (7.5; 10.6) months, respectively. The median (IQR) durations of EPBF were
20.9 (20.0; 21.5), 19.8 (12.9; 21.0), 20.9 (19.9; 21.0), 21.0 (20.6; 21.1) for Burkina Faso, South
Africa, Uganda and Zambia, respectively
The BMI of breastfeeding mothers decreased from baseline to week 26 before plateauing
until week 50 (Table 2). The same linear trend in the association between breastfeeding dura-
tion and BMI decrease was found in the country-specific analysis except in Uganda where we
did not find any significant decrease. The maximum weight loss was at week 26 (p<0.001) in
Burkina Faso and Zambia, whereas it was at week 38 for South Africa and Uganda.
Comparing the hemoglobin concentration at weeks 14 and 38, there was no overall change,
as also in the country-stratified analysis (p>0.05; see Table 3).
Categorizing women into 3 BMI groups, we found that slimmer women (BMI<18.5 kg/
m2) had no statistically significant change in their BMI postpartum (p>0.05), while the others
had significant decrease over the breastfeeding period (Table 4). The thinnest group of women
(BMI<18.5) had the steepest drop in hemoglobin at week 38; however, the difference was not
significant (-0.3 (-0.8; 0–3); see Table 5).
Factors associated with BMI changes in mothers
Overall, the univariate analysis showed that EPBF duration and all other controlled variables
were significantly associated with the BMI change, but not with the CD4 count, possibly
because the most vulnerable group, i.e. those with CD4 counts <350, were excluded from the
analysis. However, this variable was kept in the final model because of the known association
between CD4 count and HIV disease progression, usually leading to weight loss (Table 6). In
Changes in BMI and heamoglobin in HIV-1 breastfeeding mothers
PLOS ONE | https://doi.org/10.1371/journal.pone.0177259 May 9, 2017 6 / 16
the multivariate analysis shown in Table 6, no association between EPBF duration and moth-
ers’ BMI was found. Only baseline BMI, CD4 counts, education level, marital status and child
Table 1. Baseline characteristics.
A Burkina Faso South Africa Uganda Zambia All sites
N = 203 N = 212 N = 272 N = 529 N = 1216
% (95% CIa) % (95% CIa) % (95% CIa) % (95% CIa) % (95% CIa)
CD4>500 57.1 (50.2; 63.8) 51.4 (44.7; 58.1) 57.3 (51.4; 63.1) 59.9 (55.7; 64.0) 57.4 (54.6; 60.2)
Education level
Incomplete primary 68.5 (61.7; 74.5) 8.5 (5.4; 13.1) 48.5 (42.6; 54.5) 28.2 (24.5; 32.2) 36.0 (33.4; 38.8)
Completed primary 7.4 (4.5; 11.9) 0.5 (0.1; 3.3) 15.8 (11.9; 20.6) 18.5 (15.4; 22.1) 12.9 (11.1; 14.9)
Secondary and more 24.1 (18.7; 30.5) 91.0 (86.4; 94.2) 35.7 (30.2; 41.5) 53.3 (49.0; 57.5) 51.1 (48.2; 53.9)
Occupation (employed) 8.9 (5.6; 13.6) 41.5 (35.0; 48.3) 35.3 (29.8; 41.2) 17.0 (14.0; 20.5) 24.0 (21.7; 26.5)
Married/co-habiting 90.6 (85.8; 93.0) 39.1 (32.8; 45.9) 82.0 (76.9; 86.1) 88.7 (85.7; 91.1) 78.9 (76.5; 81.1)
Mode of delivery (vaginal) 93.6 (89.3; 96.2) 65.1 (58.4; 71.2) 93.4 (89.7; 95.8) 96.2 (94.2; 97.5) 89.7 (87.9; 91.3)
Parity (primiparous) 21.7 (16.5; 27.9) 33.5 (27.4; 40.1) 18.0 (13.9; 23.0) 20.6 (17.4; 24.3) 22.4 (20.2; 24.9)
Trial arm (lamivudine) 49.7 (42.9; 56.6) 51.9 (45.1; 58.6) 49.6 (43.7; 55.6) 50.3 (46.0; 54.5) 50.3 (47.5; 53.1)
HIV stage 1 93.1 (88.7; 95.9) 98.6 (95.7; 99.5) 92.3 (88.4; 94.9) 99.8 (98.7; 100.0) 96.8 (95.6; 97.6)
Child sex (male) 41.9 (35.2; 48.8) 49.1 (42.4; 55.8) 52.9 (47.0; 58.8) 48.4 (44.1; 52.7) 48.4 (45.6; 51.2)
ART prophylaxis postpartum 100.0 7.1 (4.3; 11.4) 71.0 (65.3; 76.1) 100.0 77.3 (74.9; 79.6)
Breastfeeding initiation time
Within 1st hour 6.9 (4.1; 11.3) 51.4 (44.7; 58.1) 55.9 (49.9; 61.7) 80.7 (77.1; 83.9) 57.7 (54.9; 60.5)
After 1st hour and within 1st day 64.0 (57.2; 70.4) 45.7 (39.1; 52.5) 41.2 (35.5; 47.1) 18.9 (15.8; 22.5) 36.1 (33.4; 38.8)
After 1st day 29.1 (23.2; 35.7) 2.8 (1.3; 6.2) 2.9 (1.5; 5.8) 0.4 (0.1; 1.5) 6.2 (4.9; 7.7)
EPBFb 1st 3 days 93.1 (88.7; 95.9) 94.3 (90.3; 96.8) 97.8 (95.2; 99.0) 99.0 (97.7; 99.6) 97.0 (95.8; 97.8)
EPBFb last 4 days 94.1 (89.8; 96.6) 95.7 (92.1; 97.8) 97.4 (94.7; 98.8) 99.6 (98.5; 99.9) 97.5 (96.5; 98.3)
Any BF 1st week 100.0 97.6 (94.4; 99.0) 100.0 100.0 99.6 (99.0; 99.8)
EPBFb 1st week 96.5 (92.9; 98.3) 97.2 (93.8; 98.7) 98.9 (96.6; 99.6) 99.8 (98.7;100.0) 98.6 (97.8; 99.1)
SESc tertiles
Highest tertile 31.5 (30.3 32.8) 19.8 (18.8 20.9) 38.2 (37.1 39.3) 42.3 (41.5 43.1)
Middle tertile 39.4 (38.1 40.7) 73.6 (72.4 74.7) 27.9 (26.9 29.0) 17.4 (16.8 18.0)
Lowest tertile 29.1 (27.9 30.3) 6.6 (6.0 7.3) 33.8 (32.7 34.9) 40.3 (39.5 41.1)
B
N = 203 N = 212 N = 272 N = 529 N = 1216
Median (IQRd) Median (IQRd) Median (IQRd) Median (IQRd) Median (IQRd)
Maternal age (years) 28.0 (24.3; 32.0) 27.3 (23.5; 32.8) 26.9 (23.0; 29.9) 26.8 (23.3; 31.0) 27.0 (23.3; 31.0)
BMI (kg/m2) 23.0 (21.2; 25.4) 27.8 (24.2; 31.8) 22.8 (20.8; 24.6) 23.2 (21.2; 26.5) 23.7 (21.3; 27.0)
CD4+ cells/μL 526 (428; 653) 505 (426; 648.5) 524.5 (429.5; 624) 548 (445; 705) 530 (432.5; 668.5)
Gestational age (weeks) 39.0 (37.0; 40.0) 38.0 (38.0; 38.0) 40.0 (39.0; 40.0) 38.0 (37.0; 40.0) 38.0 (38.0; 40.0)
HIV viral loade (x1000 /mL) 1.8 (0.7; 7.2) 2.1 (0.8; 7.9) 4.1 (0.6; 17.5) 3.8 (1.2; 20.6) 3.0 (0.8; 13.7)
Haemoglobin (g/dL) 11.2 (10.5; 12.1) 12.0 (11.3; 12.9) 12.4(11.7; 13.2) 12.5 (11.6; 13.3) 12.2 (11.3; 13.1)
Birth weight (kg) 2.9 (2.7; 3.2) 3.2 (2.8; 3.5) 3.0 (2.8; 3.3) 3.0 (2.8; 3.3) 3.0 (2.8; 3.3)
a Confidence Interval
b Exclusive and predominant breastfeeding
c Socio-economic status
d Interquartile range
e N = 173, 167, 180, 477 and 997 for Burkina Faso, South Africa, Uganda, Zambia and overall, respectively
f N = 175, 161, 218, 454 and 1008 for Burkina Faso, South Africa, Uganda, Zambia and overall, respectively
https://doi.org/10.1371/journal.pone.0177259.t001
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birth weight remained significant risk factors for BMI changes. Each additional kilogram of
mother’s baseline weight increased BMI by 1.0 kg/m2 during the lactation period.
Compared to mothers with a CD4 count of 350–500 cells/μl, the group with the higher
count had an increase in their BMI of 0.3 kg/m2. Regarding education level, the group that
completed primary and secondary or further education had a reduced BMI of 0.3 and 0.1 kg/
m2, respectively, over the lactation period. Eighty per cent of women in the last 2 categories
were employed compared to 18.8% among those who had zero or some years of primary
schooling. Living with a partner also conveyed a mean decrease in BMI of 0.3 kg/m2 compared
to being single. Finally, mothers of babies born with a birth weight of>3,500 g had a mean
BMI increase of 0.2 kg/m2 compared to mothers of babies with<2,500 g.
The multivariate analysis stratified by country (Table 7) shows EPBF had a significantly
decreased BMI of 0.1 kg/m2/month for Zambian participants. South Africa had exactly oppo-
site (of borderline significance) outcome of EPBF on mothers’ BMI. No effect from EPBF was
seen in the other countries. This relationship may be partially explained by the median dura-
tion of EPBF and the proportion of women still on EPBF at week 26 at the different study sites.
The median duration of EPBF was highest in Burkina Faso, Uganda and Zambia (5.8 months)
and lowest in South Africa (4.9 months). At weeks 26, 27 (13.2%), 4 (0.02%), 12 (0.04%) and
33 (0.06%) were still practicing EPBF in Burkina Faso, South Africa, Uganda and Zambia,
respectively. Conversely, baseline BMI was consistently and significantly associated with an
increase in mothers’ subsequent BMI measures in all countries throughout the lactation
period. A higher CD4 count increased BMI in Burkina Faso and Zambia, whereas an HIV
stage greater than one decreased BMI in Zambia. In the 4 countries, delivering by C-section or
delivering a girl was associated with mean BMI changes in different ways. In Burkina Faso, sin-
gle mothers had lowered BMI, whereas in South Africa it increased, these participants being in
the highest socio-economic tertile. The trial arm was not associated with any BMI change.
Table 2. Country-stratified paired t-test comparing mean BMI at different endpoints with baseline mean BMI.











BMI at week 14 minus
BMI at baseline (D7)
-0.8 (-1.1; -0.4) § -0.8 (-1.4; -0.3) § -0.2 (-0.5; 0.1) -0.5(-0.8; -0.2) § -0.5(-0.7; -0.4)§
BMI at week 26 minus
BMI at baseline (D7)
-1.1 (-2.4; 0.2) -0.8 (-1.5; -0.1) § -0.6(-0.9; -0.2) § -0.7 (-1.0; -0.3)§
BMI at week 38 minus
BMI at baseline (D7)
-0.9 (-1.5; -0.4) § -0.9 (-1.8; -0.0) § -0.4 (-0.9; 0.1) -0.6(-1.0; -0.2) § -0.7 (-0.9; -0.4)§
BMI at week 50 minus
BMI at baseline (D7)
-1.0 (-1.7; -0.2) § -0.8 (-1.7; 0.1) -0.6(-1.0; -0.2) § -0.7 (-1.0; -0.3)§
* data on mothers’ weight were missing on weeks 26 and 50 in Uganda
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t002
Table 3. Country-stratified paired t-test comparing mean hemoglobin at week 14 and week 38 (hemoglobin at week 14 > hemoglobin at week 38).
Burkina Faso South Africa Uganda Zambia All sites
Mean hemoglobin (g/dl) at W14 (95% CI) 11.2 (10.8; 11.7) 12.0 (11.5; 12.5) 12.4 (12.1; 12.8) 12.4 (12.1; 12.7) 12.1 (11.9; 12.3)
Mean hemoglobin (g/dl) at W38 (95% CI) 11.2 (10.7; 11.6) 12.1 (11.6; 12.6) 12.5 (12.2; 12.9) 12.6 (12.3; 12.8) 12.3 (12.1; 12.5)
Mean difference (g/dl) (95% CI) -0.1 (-0.5; 0.3) 0.1 (-0.3; 0.5) 0.1 (-0.2; 0.4) 0.2 (-0.1; 0.5) 0.1 (-0.1; 0.3)
https://doi.org/10.1371/journal.pone.0177259.t003
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Discussion
Considering our results, no marked change in BMI was seen in this cohort over a 26-week
period of lactation covering the EPBF period neither in the pooled analysis (Table 6) nor in the
country-stratified analysis.The mean change from 26 to 50 weeks after birth was 0.7 kg/m2 at
the paired t-test. This was also the case for changes in hemoglobin concentration. However,
the thinnest mothers had the largest change, although not statistically significant. The major
factor contributing to the biggest change in BMI was the mother’s own BMI after birth. The
heaviest mothers gained most weight during lactation. Higher birth weights and CD4 counts
correlated with some increase in BMI. Education level showed the opposite pattern, with a
higher educational status being associated with a slight reduction in BMI. In the country-strat-
ified analysis, socio-economic status was not a risk factor for BMI change, except in South
Africa where high SES was associated with an increase in BMI. However, a HIV stage above 1
correlated with a small decrease in BMI in Zambia.
The magnitude of the mean BMI decrease observed in Table 2 does not seem enough
important to have a clinical significance. The most important decrease (minus 1.1 kg/m2) was
seen in Burkina Faso at week 26. The mean BMI for this country was 23.8 (95% CI: 23.2; 24.3)
kg/m2 [data not shown]. Therefore, a decrease of 1.1 kg/m2 did not put a participant of this
site in an underweight category. This analysis was confirmed by the findings in Table 4A
where the underweight women group (<18.5 kg/m2) had a maximum non statistically-signifi-
cant weight loss of 0.5 kg/m2 smaller than the overall maximum of 1.1 kg/m2.
To the best of our knowledge, only one study [40] has tested the dose-response relationship
between breastfeeding and HIV disease progression including maternal weight loss. We also
tested whether the duration of EPBF was detrimental to the BMI of HIV-infected mothers.
Table 4. Women stratified in 3 BMI-categories: Paired t-test comparing mean BMI at different endpoints with baseline mean BMI.
BMI<18.5 N = 50 BMI between 18.5 and 24.9
N = 715









BMI at week 14<BMI at
baseline (D7)
-0.0 (-1.1; 1.0) -0.4 (-0.6; -0.2)§ -0.8 (-1.1; -0.4)§ -0.5 (-0.7; -0.4)§
BMI at week 26<BMI at
baseline (D7)
-0.2 (-1.6; 1.2) -0.6 (-1.0; -0.2)§ -0.8 (-1.3, -0.2)§ -0.7 (-1.0; -0.3)§
BMI at week 38<BMI at
baseline (D7)
-0.1 (-1.2; 0.9) -0.7 (-0.9; -0.4)§ -0.8 (-1.3; -0.2)§ -0.7 (-0.9; -0.4)§
BMI at week 50<BMI at
baseline (D7)
-0.5 (-2.1; 1.1) -0.7 (-1.2; -0.3)§ -0.6 (-1.2; -0.0)§ -0.7 (-1.0; -0.3)§
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t004
Table 5. BMI-categories-stratified paired t-test comparing mean hemoglobin at weeks 14 and 38 (hemoglobin at week 14> hemoglobin at week 38).
Number of
observations
Mean hemoglobin (g/dl) at W14
(95% CI)




BMI<18.5 36 12.1 (10.9; 13.3) 11.8 (10.7; 13.0) -0.3(-1.5; 0.9)
BMI between 18.5 and
24.9
502 12.2 (11.9; 12.5) 12.3 (12.0; 12.6) 0.1 (-0.2; 0.3)
BMI25 kg 295 12.1 (11.8; 12.42) 12.3 (12.0; 12.6) 0.2 (-0.1; 0.5)
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t005
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Other studies [28,29] compared any breastfeeding group with a formula-feeding group. A Tan-
zanian study [40], despite its loss to follow-up, concluded that neither the modality of breast-
feeding (exclusive or any), nor the duration of breastfeeding had an influence on the of
mothers with HIV infection. However, this research was focused on HIV disease progression,
and considered parameters that included maternal HIV viral load, CD4 count and weight loss.





EPBF duration -0.1 (-0.1; -0.0) -0 (0; 0)
Baseline BMI 1.0 (0.9; 1.0) § 1.0 (0.9; 1.0) §
Mother’s age 0.2 (0.1; 0.2) § 0 (0; 0)
CD4 count
<500 1 1
> = 500 0 (0; 0) 0.3 (0.2; 0.5) §
Number of children 0.4 (0.3; 0.5) § -
Number of child death -1.0 (-1.5; -0.5) § -
BF initiation time 0 (0; 0)
Within 1 hour 1 -
After 1 hour and within 1st day -0.1 (-0.4; 0.1) -
After 1st day 0.9 (0.3; 1.5) § -
Child gender
Male 1 -
Female 0.2 (0.0; 0.5) -
HIV stage
1 1 1
>1 -1.1 (-1.8; -0.3) § -0.1 (-0.4; 0.2)
Education level 0.3 (0.1; 0.5) §
No education or some primary 1 1
Complete primary 1.0 (0.6; 1.5) § -0.3 (-0.4; -0.1) §
Secondary and more 0.6 (0.3; 1.0) § -0.1 (-0.3; -0.0)
Marital status
Single 1 1
Married/cohabiting -0.9 (-1.2; -0.6) § -0.3 (-0.4; -0.2) §
Mode of delivery
Vaginal 1 -
C-section 1.8 (1.4; 2.1) § -
Parity
Primiparous 1 -
Multiparous 1.8 (1.5; 2.0) § -
Trial arm
lamivudine 1 1
lopinavir/ritonavir 0.2 (0.0; 0.4) -0.0 (-0.1; 0.0)
Child birth weight 0 (0; 0)
<2.5 kg 1 1
2.5 to 3.4 kg 1.0 (0.5; 1.4) § -0.0 (-0.2; 0.2)
> = 3.5 kg 3.2 (2.8; 3.7) § 0.2 (0.0; 0.4)
Gestational age 0.5 (0.4; 0.6) § -
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t006
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It recorded relative risks as association measures, making it difficult to compare with our
study in terms of absolute numbers. In a randomized trial on prolonged breastfeeding and
maternal mortality in Zambia [41], there seemed to be no harmful effect of breastfeeding. The
study was well designed, but its main defect lies in the failure toadhere fully to random assign-
ment by the participants, although the investigators deemed this had no significant effect on
the findings. Another analysis of the same Zambian data [27] over 2 years, in which there was
control for confounding, such as SES, obstetric history, season and food shortage, reported net
weight gain rather than weight loss, which has also been found in undernourished lactating
mothers [25,42,43]. Hartmann [43] explained this weight gain by a “homeorhetic theory of
metabolic adjustment” in favor of a dominant physiological state such as lactation. This may
also explain why the thinnest mothers did not lose weight during EPBF period in our cohort.
However, we do not have sufficient data to address issues such as food shortages, or other prac-
tical or mental issues, that could have led to the underweight status in the first place.
Table 7. Multivariate country-stratified analysis testing BMI change in breastfeeding mothers over the duration of extended EBF.
Adjusted Coefficient (95% CI)
Burkina Faso South Africa Uganda Zambia
EPBF duration 0.0 (-0.1; 0.2) 0.1 (-0.0; 0.1) -0.0 (-0.1; 0.1) -0.1 (-0.1; -0.0)
Baseline BMI 0.9 (0.9; 1.0) § 1.0 (0.9; 1.0) § 1.0 (0.9; 1.0) § 1.0 (0.9; 1.0) §
Mothers’ age -0.0 (-0.0; 0.0) 0.0 (-0.0; 0.1) -0.00 (-0.0; 0.0) -0.0 (-0.0; 0.0)
CD4 count
<500 1 1 1 1
> = 500 0.5 (0.2; 0.8) § 0.2 (-0.1; 0.4) 0.1 (-0.1; 0.4) 0.2 (0.0; 0.4)
Child sex
Male 1 1 1 1
Female -0.4(-0.6;-0.1) § 0.5 (0.1; 0.9) § -0.5 (-0.8; -0.2) § -0.8 (-1.8; 0.1)
HIV stage
1 1 1 1 1
>1 0.4 (-0.1; 0.8) 0.6 (-0.4; 1.6) -0.0 (-0.1; 0.1) -0.1 (-0.1; -0.0)
Marital status
Single 1 1 1 1
Married/cohabiting -1.0 (-1.5; -0.5) § - - -
Mode of delivery
Vaginal 1 1 1 1
C-section -0.5 (-1.0; -0.1) § 0.6 (0.0; 1.2)
Trial arm
lamivudine 1 1 1 1
lopinavir/ritonavir -0.0 (-0.3; 0.3) 0.2 (-0.2; 0.6) -0.16 (-0.3; 0.0) -0.2 (-0.4; 0.0)
Child birth weight
<2.5 kg 1 1
> = 2.5 to 3.4 kg 0.1 (-0.4; 0.6) -0.5 (-1.2; 0.2) -0.1 (-0.6; 0.3) 0.3 (-0.1; 0.8)
> = 3.5 kg 0.3 (-0.3; 0.9) 0.0 (-0.7; 0.8) 0.2 (-0.7; 0.2) 0.4 (-0.2; 0.9)
SES (tertiles)
Highest tertile 1
Middle tertile -0.3 (-0.6; 0.0) 0.0 (-0.5; 0.5) 0.2 (-0.4; 0.1) -0.1 (-0.4; 0.1)
Lowest tertile 0.0 (-0.3; 0.4) 0.6 (0.1; 1.1) § 0.2 (-0.0; 0.5) 0.2 (-0.1; 0.6)
§ Significant results
https://doi.org/10.1371/journal.pone.0177259.t007
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Our study did not have a non-breastfeding group for comparison, and therefore cannot
confirm or refute the findings from Kenya [28,29], where breastfeeding women were found
that lose more weight than non-breastfeeding ones. Another study in South Africa [44] showed
that breastfeeding HIV-positive mothers lost more weight than breastfeeding HIV-negative
mothers. In addition to the limitations of the study (including the lack of power of the study),
the design did not truly allow attribution of the weight change to the breastfeeding factor,
since it did not compare breastfeeding and formula groups, nor assess a dose-response by con-
sidering the duration of breastfeeding; instead, the study compared cross-sectional data at dif-
ferent time points.
The different studies referred to above were not directly comparable, mainly because of dif-
ferences in follow-up time. It was 24 months in the Vertical Transmission Study [14]; 20
months in the Zambian study with follow-up starting at 4 months post-partum [27]; and 6
months in the Kesho Bora trial [24]. The Kenyan studies had a number of methodological
issues [45].
In an analysis of 2 sets of data from Honduras [46], EBF did not affect maternal weight loss
in one study regarding 119 full-term low birth-weight infants. In the second study of 141
infants of low-income primiparous women, the EBF group lost more weight than mothers
feeding their children with solid foods between 4 and 6 months of age. Being of a low income
group could contribute to poor dietary intake, thereby contributing to the weight loss. The
study design may not have controlled properly all potential confounders.
Validity of our findings
This analysis was done on data collected from a large sample of HIV-positive mothers from 4
different countries in a clinical trial setting. However, the rigorous selection criteria may have
resulted in a recruited a study population that was not strictly representative of the general
population. Hence, the association between the HIV stage and BMI change may not reflect
that in the general population of HIV-positive mothers, since only patients with CD4 counts
above 350 and at stage 1 or 2 were included, and almost all of them remained at the same
asymptomatic stage until the end of the study. The SES index calculation proved challenging
because the study environments in the 4 countries were diverse; for this reason we built a
country-specific SES since a pooled 4-country index was not meaningful. Moreover, the clini-
cal trial context was not the routine or standard care environments for most women, which
may have distorted the SES effect on BMI change. However, these issues were less likely to
influence the association between EPBF duration and BMI change.
It is also possible that some reporting bias regarding our variable of interest was involved,
since in some sites (e.g. Burkina Faso), the study team in charge of nutritional counseling also
collected the breastfeeding data. No data was collected to validate the mothers’ reports of their
own feeding practices. We dropped all subjects without breastfeeding data or with obvious
inaccurate data to partially mitigate this issue.
We also failed to consider the mothers’ daily food intake and physical activities as important
factors in our assessment of BMI change. Nevertheless, we believe that the nutritional, finan-
cial (transport costs) and technical support provided to all participants in the trial, combined
with the relative homogeneity of our study population tended to minimize the effect of dispari-
ties in general and also those that were eventually related to food intake and physical activities.
Conclusion
Breastfeeding did not affect the BMI in HIV-1 infected Sub-Saharan African mothers when
their CD4 counts were >350 cells/μl. However, a higher baseline BMI and a CD4 count >500
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cells/μl led to an increase in BMI during the EPBF period. Considering the benefits of breast
milk for infants, and the recurrent results from different studies elsewhere that breastfeeding
does not harm HIV-1-infected mothers, this study also supports the WHO 2016 guidelines on
infant feeding, which indicates that mothers living with HIV should breastfeed for at least 12
months and up to 24 months, provided that the right treatment or prophylaxis for the infection
is given where formula feeding is unsafe.
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